Key result
Among pediatric patients treated with high-dose doxorubicin, acute intercurrent viral illness triggered a sudden, late decrease in fractional shortening in 5 of 7 patients.
Why the study?
Does acute intercurrent viral illness trigger late cardiotoxicity in pediatric patients previously treated with doxorubicin?
Cohort (n=30)
Does acute intercurrent viral illness trigger late cardiotoxicity in pediatric patients previously treated with doxorubicin?
Answers are grounded in this paper and cite their sources.
Acute intercurrent viral illness may act as a trigger for late, sudden cardiac dysfunction in pediatric patients with subclinical cardiac damage from high-dose doxorubicin.
BACKGROUND: The most frequently encountered doxorubicin related cardiac toxicity is a dose-related myocardial dysfunction occurring 1-6 months after chemotherapy. Recently, late cardiotoxicity has been the focus of interest. This paper explores the possibility that acute intercurrent viral illness may trigger late cardiotoxicity. METHODS: Thirty selected pediatric patients were followed for changes in their echocardiographically measured fractional shortening (FS) for 2-10 years after completion of their doxorubicin chemotherapy. They were divided according to the dose of doxorubicin they received (< 300 mg/m2 or > or = 300 mg/m2) and to whether the manifestations of an acute intercurrent viral illness during the observation period were documented. Eleven patients experienced such infections. RESULTS: Changes in FS demonstrated two different responses. The usual response to doxorubicin was a gradual, dose-related fall in FS, followed by recovery; while the second response included an unexpected, late, sudden decrease in FS. Four patients in the low dose subgroup experienced an acute intercurrent viral illness, but none of these demonstrated the unexpected decrease. Of the seven patients who acquired such illness in the high dose subgroup, five demonstrated the sudden, late decrease in FS, with two of them developing severe, reversible congestive heart failure. CONCLUSIONS: The most likely explanation for the late, sudden decrease in FS is an additional stress in patients who already have sustained subclinical cardiac damage as a result of their doxorubicin chemotherapy. An acute intercurrent viral illness may have triggered late cardiac dysfunction in some of these patients.
No takes yet. Share an insight, caveat, or question.
Ali et al. (1994) conducted a cohort in Late doxorubicin-associated cardiotoxicity (n=30). Acute intercurrent viral illness vs. No acute intercurrent viral illness was evaluated on Changes in echocardiographically measured fractional shortening (FS). Among pediatric patients treated with high-dose doxorubicin, acute intercurrent viral illness triggered a sudden, late decrease in fractional shortening in 5 of 7 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: